中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 7
Jul.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(7): 1724-1728

Role of microRNA-122 in the development, progression, and diagnosis of liver disease

DOI: 10.3969/j.issn.1001-5256.2021.07.052
  • 1.

    Graduate School, Guangxi University of Chinese Medicine, Nanning 530001, China

  • 2a.

    Department of Infectious Diseases, Ruikang Hospital, Guangxi University of Chinese Medicine, Nanning 530001, China

  • 2b.

    Department of Science and Technology, Ruikang Hospital, Guangxi University of Chinese Medicine, Nanning 530001, China

  • 2c.

    Department of Gastroenterology, Ruikang Hospital, Guangxi University of Chinese Medicine, Nanning 530001, China

  • 3.

    Department of Endocrinology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530001, China

Research funding:

National Natural Science Foundation of China (81860790);

Guangxi Natural Science Foundation of China (2017GXNSFAA198183)

  • Received Date: 2020-12-03
  • Accepted Date: 2020-12-25
  • Published Date: 2021-07-20
    Abstract
  • MicroRNA is a type of small non-coding RNA that participates in multiple links such as cell proliferation and apoptosis by regulating gene expression after transcription. More and more studies have shown that microRNA-122 (miRNA-122) is involved in the development and progression of a variety of liver diseases. With reference to related reports in the literature, this article summarizes advances in the role of miRNA-122 in various liver diseases including nonalcoholic fatty liver disease, hepatitis, liver fibrosis, and liver cancer and analyzes the potential of miRNA-122 as a new noninvasive biomarker, so as to provide a reference for exploring the diagnosis and treatment of liver disease.

     

    • FullText(HTML)
  • loading
    • References(53)
  • [1]
    MATSUYAMA H, SUZUKI HI. Systems and synthetic microRNA biology: From biogenesis to disease pathogenesis[J]. Int J Mol Sci, 2019, 21(1): 132. DOI: 10.3390/ijms21010132.
    [2]
    ZHAO Y, WANG Z, ZHANG W, et al. MicroRNAs play an essential role in autophagy regulation in various disease phenotypes[J]. Biofactors, 2019, 45(6): 844-856. DOI: 10.1002/biof.1555.
    [3]
    LEE RC, FEINBAUM RL, AMBROS V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J]. Cell, 1993, 75(5): 843-854. DOI: 10.1016/0092-8674(93)90529-y.
    [4]
    FIRE A, XU S, MONTGOMERY MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans[J]. Nature, 1998, 391(6669): 806-811. DOI: 10.1038/35888.
    [5]
    LAGOS-QUINTANA M, RAUHUT R, LENDECKEL W, et al. Identification of novel genes coding for small expressed RNAs[J]. Science, 2001, 294(5543): 853-858. DOI: 10.1126/science.1064921.
    [6]
    KOZOMARA A, GRIFFITHS-JONES S. miRBase: Annotating high confidence microRNAs using deep sequencing data[J]. Nucleic Acids Res, 2014, 42(Database issue): d68-d73. DOI: 10.1093/nar/gkt1181.
    [7]
    LAGOS-QUINTANA M, RAUHUT R, YALCIN A, et al. Identification of tissue-specific microRNAs from mouse[J]. Curr Biol, 2002, 12(9): 735-739. DOI: 10.1016/s0960-9822(02)00809-6.
    [8]
    YOUNOSSI ZM. Non-alcoholic fatty liver disease - A global public health perspective[J]. J Hepatol, 2019, 70(3): 531-544. DOI: 10.1016/j.jhep.2018.10.033.
    [9]
    YAMADA H, SUZUKI K, ICHINO N, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver[J]. Clin Chim Acta, 2013, 424: 99-103. DOI: 10.1016/j.cca.2013.05.021.
    [10]
    LONG JK, DAI W, ZHENG YW, et al. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease[J]. Mol Med, 2019, 25(1): 26. DOI: 10.1186/s10020-019-0085-2.
    [11]
    PURUSHOTHAM A, SCHUG TT, XU Q, et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation[J]. Cell Metab, 2009, 9(4): 327-338. DOI: 10.1016/j.cmet.2009.02.006.
    [12]
    LI X. SIRT1 and energy metabolism[J]. Acta Biochim Biophys Sin(Shanghai), 2013, 45(1): 51-60. DOI: 10.1093/abbs/gms108.
    [13]
    WANG S, QIU L, YAN X, et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1)-modulated P53 activity[J]. Hepatology, 2012, 55(3): 730-741. DOI: 10.1002/hep.24809.
    [14]
    QU JH, ZHU MH, LIN J, et al. Effects of hepatitis B virus on p53 expression in hepatoma cell line SMMU-7721[J]. World J Gastroenterol, 2005, 11(39): 6212-6215. DOI: 10.3748/wjg.v11.i39.6212.
    [15]
    CHEN Y, SHEN A, RIDER PJ, et al. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication[J]. FASEB J, 2011, 25(12): 4511-4521. DOI: 10.1096/fj.11-187781.
    [16]
    XU H, XU SJ, XIE SJ, et al. MicroRNA-122 supports robust innate immunity in hepatocytes by targeting the RTKs/STAT3 signaling pathway[J]. Elife, 2019, 8. DOI: 10.7554/eLife.41159.
    [17]
    WACK A, TERCZYŃSKA-DYLA E, HARTMANN R. Guarding the frontiers: The biology of type Ⅲ interferons[J]. Nat Immunol, 2015, 16(8): 802-809. DOI: 10.1038/ni.3212.
    [18]
    LI XD, SUN L, SETH RB, et al. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity[J]. Proc Natl Acad Sci U S A, 2005, 102(49): 17717-17722. DOI: 10.1073/pnas.0508531102.
    [19]
    GERRESHEIM GK, DVNNES N, NIEDER-RÖHRMANN A, et al. microRNA-122 target sites in the hepatitis C virus RNA NS5B coding region and 3' untranslated region: Function in replication and influence of RNA secondary structure[J]. Cell Mol Life Sci, 2017, 74(4): 747-760. DOI: 10.1007/s00018-016-2377-9.
    [20]
    HE YJ, HUANG ML, LE Y, et al. Effect of myricitrin on replication of hepatitis C virus through microRNA-122[J]. Pharmacol Clin Chin Materia Med, 2020, 36(4): 99-102. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYL202004019.htm

    何玉娇, 黄茂林, 乐燕, 等. 杨梅苷通过microRNA-122对丙型肝炎病毒复制的影响[J]. 中药药理与临床, 2020, 36(4): 99-102. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYL202004019.htm
    [21]
    KATAREY D, VERMA S. Drug-induced liver injury[J]. Clin Med (Lond), 2016, 16(Suppl 6): s104-s109. DOI: 10.7861/clinmedicine.16-6-s104.
    [22]
    LI LN, LI Y, PENG JY. microRNA and drug-induced liver injury[J]. Chin J Clin Pharmacol Ther, 2020, 25(7): 803-809. DOI: 10.12092/j.issn.1009-2501.2020.07.013.

    许丽娜, 李月, 彭金咏. microRNA与药物性肝损伤[J]. 中国临床药理学与治疗学, 2020, 25(7): 803-809. DOI: 10.12092/j.issn.1009-2501.2020.07.013.
    [23]
    CHOWDHARY V, TENG KY, THAKRAL S, et al. miRNA-122 protects mice and human hepatocytes from acetaminophen toxicity by regulating cytochrome P450 family 1 subfamily a member 2 and family 2 subfamily E member 1 expression[J]. Am J Pathol, 2017, 187(12): 2758-2774. DOI: 10.1016/j.ajpath.2017.08.026.
    [24]
    Liver Disease Committee, Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of liver fibrosis with integrated traditional Chinese and Western medicine (2019 edition)[J]. J Clin Hepatol, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.

    中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.
    [25]
    YANG AT, HU DD, WANG P, et al. TGF-β1 induces the dual regulation of hepatic progenitor cells with both anti- and proliver fibrosis[J]. Stem Cells Int, 2016, 2016: 1492694. DOI: 10.1155/2016/1492694.
    [26]
    LI JH, HUANG XR, ZHU HJ, et al. Role of TGF-beta signaling in extracellular matrix production under high glucose conditions[J]. Kidney Int, 2003, 63(6): 2010-2019. DOI: 10.1046/j.1523-1755.2003.00016.x.
    [27]
    CHENG B, ZHU Q, LIN W, et al. MicroRNA-122 inhibits epithelial-mesenchymal transition of hepatic stellate cells induced by the TGF-β1/Smad signaling pathway[J]. Exp Ther Med, 2019, 17(1): 284-290. DOI: 10.3892/etm.2018.6962.
    [28]
    WANG SC, LIN XL, LI J, et al. MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA[J]. PLoS One, 2014, 9(7): e101330. DOI: 10.1371/journal.pone.0101330.
    [29]
    CSAK T, BALA S, LIPPAI D, et al. microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis[J]. Liver Int, 2015, 35(2): 532-541. DOI: 10.1111/liv.12633.
    [30]
    LU SC, AKANJI AO. Leptin, obesity, and hypertension: A review of pathogenetic mechanisms[J]. Metab Syndr Relat Disord, 2020, 18(9): 399-405. DOI: 10.1089/met.2020.0065.
    [31]
    BENBAIBECHE H, BOUNIHI A, KOCEIR EA. Leptin level as a biomarker of uncontrolled eating in obesity and overweight[J]. Ir J Med Sci, 2021, 190(1): 155-161. DOI: 10.1007/s11845-020-02316-1.
    [32]
    DUAN DM, JHANG JY, WU S, et al. Modification effect of sex and obesity on the correlation of LEP polymorphisms with leptin levels in Taiwanese obese women[J]. Mol Genet Genomic Med, 2020, 8(3): e1113. DOI: 10.1002/mgg3.1113.
    [33]
    CAO Q, ZHU X, ZHAI X, et al. Leptin suppresses microRNA-122 promoter activity by phosphorylation of FOXO1 in hepatic stellate cell contributing to leptin promotion of mouse liver fibrosis[J]. Toxicol Appl Pharmacol, 2018, 339: 143-150. DOI: 10.1016/j.taap.2017.12.007.
    [34]
    MATTIUZZI C, LIPPI G. Current cancer epidemiology[J]. J Epidemiol Glob Health, 2019, 9(4): 217-222. DOI: 10.2991/jegh.k.191008.001.
    [35]
    SZABO G, BALA S. MicroRNAs in liver disease[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(9): 542-552. DOI: 10.1038/nrgastro.2013.87.
    [36]
    YAHYA S, FATHY SA, EL-KHAYAT ZA, et al. Possible role of microRNA-122 in modulating multidrug resistance of hepatocellular carcinoma[J]. Indian J Clin Biochem, 2018, 33(1): 21-30. DOI: 10.1007/s12291-017-0651-8.
    [37]
    BAI S, NASSER MW, WANG B, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib[J]. J Biol Chem, 2009, 284(46): 32015-32027. DOI: 10.1074/jbc.M109.016774.
    [38]
    YANG G, ZHANG M, ZHAO Y, et al. HNF-4α inhibits hepatocellular carcinoma cell proliferation through miR-122-adam17 pathway[J]. PLoS One, 2020, 15(3): e0230450. DOI: 10.1371/journal.pone.0230450.
    [39]
    ZHANG S, LIN YH, TARLOW B, et al. The origins and functions of hepatic polyploidy[J]. Cell Cycle, 2019, 18(12): 1302-1315. DOI: 10.1080/15384101.2019.1618123.
    [40]
    MARGALL-DUCOS G, CELTON-MORIZUR S, COUTON D, et al. Liver tetraploidization is controlled by a new process of incomplete cytokinesis[J]. J Cell Sci, 2007, 120(Pt 20): 3633-3639. DOI: 10.1242/jcs.016907.
    [41]
    GUIDOTTI JE, BRÉGERIE O, ROBERT A, et al. Liver cell polyploidization: A pivotal role for binuclear hepatocytes[J]. J Biol Chem, 2003, 278(21): 19095-19101. DOI: 10.1074/jbc.M300982200.
    [42]
    DONNE R, SAROUL-AÏNAMA M, CORDIER P, et al. Polyploidy in liver development, homeostasis and disease[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(7): 391-405. DOI: 10.1038/s41575-020-0284-x.
    [43]
    ZHANG S, ZHOU K, LUO X, et al. The polyploid state plays a tumor-suppressive role in the liver[J]. Dev Cell, 2018, 47(3): 390. DOI: 10.1016/j.devcel.2018.10.020.
    [44]
    LIN YH, ZHANG S, ZHU M, et al. Mice with increased numbers of polyploid hepatocytes maintain regenerative capacity but develop fewer hepatocellular carcinomas following chronic liver injury[J]. Gastroenterology, 2020, 158(6): 1698-1712.e14. DOI: 10.1053/j.gastro.2020.01.026.
    [45]
    HSU SH, DELGADO ER, OTERO PA, et al. MicroRNA-122 regulates polyploidization in the murine liver[J]. Hepatology, 2016, 64(2): 599-615. DOI: 10.1002/hep.28573.
    [46]
    GUO BH, WU DD, KUANG YL. SF, 25-OH Vit D and miR-122 levels in patients with NAFLD expression and clinical significance[J]. Chin Foreign Med Res, 2020, 18(6): 153-156. DOI: 10.14033/j.cnki.cfmr.2020.06.065.

    郭笔红, 吴丹丹, 邝燕玲. SF、25-OH Vit D及miR-122水平在NAFLD患者中表达及临床意义[J]. 中外医学研究, 2020, 18(6): 153-156. DOI: 10.14033/j.cnki.cfmr.2020.06.065.
    [47]
    OMRAN AA, OSMAN KS, KAMEL HM, et al. MicroRNA-122 as a novel non-invasive marker of liver fibrosis in hepatitis C virus patients[J]. Clin Lab, 2016, 62(7): 1329-1337. DOI: 10.7754/Clin.Lab.2015.151141.
    [48]
    WANG K, ZHANG S, MARZOLF B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury[J]. Proc Natl Acad Sci U S A, 2009, 106(11): 4402-4407. DOI: 10.1073/pnas.0813371106.
    [49]
    MCGILL MR, SHARPE MR, WILLIAMS CD, et al. The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation[J]. J Clin Invest, 2012, 122(4): 1574-1583. DOI: 10.1172/JCI59755.
    [50]
    ANTOINE DJ, DEAR JW, LEWIS PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital[J]. Hepatology, 2013, 58(2): 777-787. DOI: 10.1002/hep.26294.
    [51]
    DEAR JW, CLARKE JI, FRANCIS B, et al. Risk stratification after paracetamol overdose using mechanistic biomarkers: Results from two prospective cohort studies[J]. Lancet Gastroenterol Hepatol, 2018, 3(2): 104-113. DOI: 10.1016/S2468-1253(17)30266-2.
    [52]
    FRANCK M, SCHÁTTE K, MALFERTHEINER P, et al. Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factor[J]. World J Gastroenterol, 2020, 26(1): 86-96. DOI: 10.3748/wjg.v26.i1.86.
    [53]
    ZHAO XF, LI N, LIN DD, et al. Circulating microRNA-122 for the diagnosis of hepatocellular carcinoma: A meta-analysis[J]. Biomed Res Int, 2020, 2020: 5353695. DOI: 10.1155/2020/5353695.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (958) PDF downloads(103) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return